US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Direxion Daily Biotech Top 5 Bull 2X ETF

36.95

-0.9597-2.53%

Post-market: 36.950.00000.00%16:10 EDT

Volume:799

Turnover:29.62K

Market Cap:2.77M

PE:- -

High:37.04

Open:37.04

Low:36.95

Close:37.91

52wk High:45.88

52wk Low:25.71

Shares:75.00K

Float Shares:75.00K

Volume Ratio:0.71

T/O Rate:1.07%

Dividend:0.76

Dividend Rate:2.07%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Vertex Pharmaceuticals Incorporated : Jefferies Raises Target Price to $640 from $633

THOMSON REUTERS

Gilead Sciences Inc. Stock Outperforms Competitors on Strong Trading Day

Aytu BioPharma Q4 Revenue Beats Analyst Estimates on EXXUA Sales

Vertex's Kidney Drug Success Sparks a 22% Surge for This Rival Biotech

Update: US Equity Indexes, Crude Oil Prices Mixed in Midday Trading

MT Newswires Live

Analysts Offer Insights on Healthcare Companies: Eledon Pharmaceuticals (ELDN), Viking Therapeutics (VKTX) and Amgen (AMGN)

Amgen Inc Stock (AMGN) Moved Up by 3.90% on Sep 22: Facts Behind the Movement

Competitive profile of Amgen’s dazodalibep still ‘open question,’ says Citi

Truist sees ‘significant positive readthrough’ for Maze from Vertex data

Maze jumps 25% to $27.99 after Vertex kidney disease data

Amgen Rises After Autoimmune Drug Meets Late-Stage Trial Goal

Amgen Says Dazodalibep Meets Primary Endpoint in Phase 3 Sjögren's Disease Trial

Amgen Shares up 3% After Co's Autoimmune Disease Drug Succeeds in Late-Stage Trial

THOMSON REUTERS

Amgen Says Phase 3 Trial Shows Dazodalibep Cuts Systemic Disease Activity in Sjögren’s Disease

Vertex Pharmaceuticals Incorporated Says Inaxaplin Reduces UACR by -42.7% at Week 13 in AMKD with Modest Proteinuria

Amgen Announces Positive Topline Phase 3 Results for Dazodalibep in Moderate-to-Severe Systemic SjÖGren's Disease

THOMSON REUTERS

Amgen: Dazodalibep Showed Statistically Significant & Clinically Meaningful Improvement in Systemic Disease Activity

THOMSON REUTERS

Amgen: Phase 3 Oasiz 303 Study of Dazodalibep in Moderate-to-Severe Symptomatic SjÖGren’s Disease Expected to Complete in Q4 2026

THOMSON REUTERS

Vertex Pharmaceuticals Reports Positive Results for Inaxaplin Kidney Disease Trial

MT Newswires Live

Vertex Pharmaceuticals announces positive results from Phase 2b inaxaplin study

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/TBXU/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TBXU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TBXU\",,,,,undefined,":{"symbol":"TBXU","market":"US","secType":"STK","nameCN":"Direxion Daily Biotech Top 5 Bull 2X ETF","latestPrice":36.95,"timestamp":1790971200000,"preClose":37.9097,"halted":0,"volume":799,"hourTrading":{"tag":"盘后","latestPrice":36.95,"preClose":36.95,"latestTime":"16:10 EDT","volume":7,"amount":258.65,"timestamp":1790971805107,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.025315420591563585,"floatShares":75001,"shares":75001,"eps":0,"marketStatus":"Market Closed","change":-0.9597,"latestTime":"10-02 16:00:00 EDT","open":37.04,"high":37.04,"low":36.95,"amount":29615,"amplitude":0.002374,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":2,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791187200000},"marketStatusCode":7,"adr":0,"exchange":"ARCA","adjPreClose":37.9097,"sharesOutstanding":100001,"nav":37.787,"aum":2834038.05,"dividendRate":0.020691,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":39.28,"preClose":37.9097,"latestTime":"08:40 EDT","volume":3,"amount":117.84,"timestamp":1790944836091,"change":1.3703,"changeRate":0.036146,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":36.95,"preClose":36.95,"latestTime":"16:10 EDT","volume":7,"amount":258.65,"timestamp":1790971805107,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.7050829571574564},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TBXU\",,,,,undefined,":{"symbol":"TBXU","floatShares":75001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.7050829571574564,"shares":75001,"dividePrice":0.76452,"high":37.04,"amplitude":0.002374,"preClose":37.9097,"low":36.95,"week52Low":25.71,"pbRate":"--","week52High":45.88,"institutionHeld":0,"latestPrice":36.95,"eps":0,"divideRate":0.020691,"volume":799,"delay":0,"ttmEps":0,"open":37.04,"prevYearClose":31.065,"prevWeekClose":40.5306,"prevMonthClose":39.9,"prevQuarterClose":39.9,"fiveDayClose":40.5306,"twentyDayClose":45.76,"sixtyDayClose":33.8804},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TBXU\",params:#limit:5,,,undefined,":[{"date":"2026-09-22","symbol":"TBXU","amount":0.14204,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-22","defaultRemindTime":1790083800000,"name":"Direxion Daily Biotech Top 5 Bull 2X ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-29","payableDate":"2026-09-22","currency":"USD","dateTimestamp":1790049600000,"payDate":"2026-09-29"},{"date":"2026-06-23","symbol":"TBXU","amount":0.11101,"announcedDate":"2026-06-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-23","defaultRemindTime":1782221400000,"name":"Direxion Daily Biotech Top 5 Bull 2X ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-30","payableDate":"2026-06-23","currency":"USD","dateTimestamp":1782187200000,"payDate":"2026-06-30"},{"date":"2026-03-24","symbol":"TBXU","amount":0.09893,"announcedDate":"2026-03-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-24","defaultRemindTime":1774359000000,"name":"Direxion Daily Biotech Top 5 Bull 2X ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-31","payableDate":"2026-03-24","currency":"USD","dateTimestamp":1774324800000,"payDate":"2026-03-31"},{"date":"2025-12-23","symbol":"TBXU","amount":0.10111,"announcedDate":"2025-12-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-23","defaultRemindTime":1766500200000,"name":"Direxion Daily Biotech Top 5 Bull 2X ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-31","payableDate":"2025-12-23","currency":"USD","dateTimestamp":1766466000000,"payDate":"2025-12-31"},{"date":"2025-12-10","symbol":"TBXU","amount":0.31143,"announcedDate":"2025-12-09","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-10","defaultRemindTime":1765377000000,"name":"Direxion Daily Biotech Top 5 Bull 2X ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-17","payableDate":"2025-12-10","currency":"USD","dateTimestamp":1765342800000,"payDate":"2025-12-17"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TBXU\",market:\"US\",,,undefined,":[{"executeDate":"2025-12-10","recordDate":"2025-12-10","paymentDate":"2025-12-17","value":0.31143,"currency":"USD"},{"executeDate":"2025-12-23","recordDate":"2025-12-23","paymentDate":"2025-12-31","value":0.10111,"currency":"USD"},{"executeDate":"2026-03-24","recordDate":"2026-03-24","paymentDate":"2026-03-31","value":0.09893,"currency":"USD"},{"executeDate":"2026-06-23","recordDate":"2026-06-23","paymentDate":"2026-06-30","value":0.11101,"currency":"USD"},{"executeDate":"2026-09-22","recordDate":"2026-09-22","paymentDate":"2026-09-29","value":0.14204,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TBXU\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TBXU\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2669999174","title":"Vertex Pharmaceuticals Incorporated : Jefferies Raises Target Price to $640 from $633","url":"https://stock-news.laohu8.com/highlight/detail?id=2669999174","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669999174?lang=en_us&edition=fundamental","pubTime":"2026-09-23 11:36","pubTimestamp":1790134588,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nFWN45E0RF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SG9999013999.USD","IE00B4R5TH58.HKD","BK4139","LU1585245621.USD","LU0109394709.USD","BBH","SGXZ57979304.SGD","IE0002270589.USD","IE00B19Z9Z06.USD","IE00B894F039.SGD","PBE","IDNA","IBBQ","SG9999001176.USD","LU1674673428.USD","LU0889565916.HKD","IE00BJT1NW94.SGD","BIB","IE00BZ9MQY76.HKD","LU1093756325.SGD","LU2456880835.USD","LU2417539215.USD","BK4588","IE00B19Z3B42.SGD","LU2468319806.SGD","LU1035775433.USD","LU1069344957.HKD","LU0432979614.USD","IE00B19Z3581.USD","IE0002141913.USD","GNMX","IE00B19Z9P08.USD","BK4567","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","TBXU","LU0320765992.SGD","LU1093756168.USD","IBB","IE0009355771.USD","LU0061475181.USD","LU1778281490.HKD","VRTX","LU2362541273.HKD","LU0234570918.USD","BK4585","LU2462157665.USD","LU2362540622.SGD","LU2237438978.USD","LU0058720904.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669171122","title":"Gilead Sciences Inc. Stock Outperforms Competitors on Strong Trading Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2669171122","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669171122?lang=en_us&edition=fundamental","pubTime":"2026-09-23 04:34","pubTimestamp":1790109240,"startTime":"0","endTime":"0","summary":"DJ Gilead Sciences Inc. Stock Outperforms Competitors On Strong Trading DayThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Gilead Sciences Inc.  rallied 1.40% to $152.67 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index  remaining mostly unchanged at 7,764.64 and the Dow Jones Industrial Average  falling 0.36% to 51,863.69.This was the stock's second consecutive day of gains.Gilead Sciences Inc. closed 2.94% below its 52-week high of $157.29, which the company achieved on February 11th.The stock outperformed some of its competitors Tuesday, as Johnson & Johnson  fell 0.10% to $269.19, Pfizer Inc.  rose 0.68% to $27.93, and Abbott Laboratories  rose 0.69% to $103.69.Trading volume  remained 1.3 million below its 50-day average volume of 6.2 M.Data source: Dow Jones Market Data, FactSet. Data compiled September 22, 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0965509010.AUD","IE00B7SZLL34.SGD","LU0861579265.USD","LU1934455863.HKD","LU2324357040.USD","BK4583","LU1057294990.SGD","LU2087621335.USD","SG9999015952.SGD","LU1430594728.SGD","LU1674673428.USD","BMED","IE00B19Z3581.USD","LU1778281490.HKD","BIB","LU0965509283.SGD","SG9999015986.USD","LU1571399168.USD","LU0122379950.USD","TMED","BK4566","LU1061106388.HKD","BK4585","LU1066051498.USD","LU1585245621.USD","LU1934455194.USD","LU2089984988.USD","BK4588","LU1037948897.HKD","LU0889565916.HKD","LU1934455277.USD","IE00B3T34201.USD","LU2112291526.USD","BBH","MEDI","LU0109394709.USD","LU0965508806.USD","BK4578","LU1037948541.HKD","BK4568","SG9999015978.USD","IBBQ","LU0114720955.EUR","LU2468319806.SGD","IBB","IE00BSNM7G36.USD","SG9999015945.SGD","BK4532","LU0965509101.SGD","LU1066053197.SGD","BK4139","LU0859254822.USD","IE00BZ1G4Q59.USD","BK4550","IE00B19Z3B42.SGD","IE00BKVL7J92.USD","LU0289739699.SGD","LU0320765992.SGD","LU0823416689.USD","LU1839511570.USD","LU2357627491.SGD","LU1023059063.AUD","GILD","IE0002270589.USD","LU0882574055.USD","LU0234570918.USD","LU0058720904.USD","LU1674673691.USD","TBXU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669577122","title":"Aytu BioPharma Q4 Revenue Beats Analyst Estimates on EXXUA Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2669577122","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669577122?lang=en_us&edition=fundamental","pubTime":"2026-09-23 04:17","pubTimestamp":1790108275,"startTime":"0","endTime":"0","summary":"Aytu BioPharma Q4 revenue beats analyst estimates on EXXUA salesOverviewUS pharmaceutical firm's fiscal Q4 revenue rose 6.4%, beating analyst expectationsCompany reported near break-even net loss for ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nL1N45E0WU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1571399168.USD","TBXU","IE00B4R5TH58.HKD","LU1061106388.HKD","IE0009355771.USD","LU2468319806.SGD","BK4007","LU1057294990.SGD","IE00BJT1NW94.SGD","IE0002141913.USD","IE00B2B36J28.USD","LU0122379950.USD","LU0889565916.HKD","LU2242652126.USD","BK4534","LU1023059063.AUD","LU0868494617.USD","PBE","BK4588","AMGN","BK4581","IBBQ","LU2112291526.USD","SG9999001440.SGD","LU0320765992.SGD","LU0058720904.USD","PJP","BIB","LU1983299246.USD","IE00BJJMRZ35.SGD","BK4566","BK4139","LU0109394709.USD","AYTU","BK4533","BBH","IE00BFTCPJ56.SGD","BK4599","LU0289739699.SGD","BK4585","IBB","LU2242646821.SGD","LU2089984988.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669412656","title":"Vertex's Kidney Drug Success Sparks a 22% Surge for This Rival Biotech","url":"https://stock-news.laohu8.com/highlight/detail?id=2669412656","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669412656?lang=en_us&edition=fundamental","pubTime":"2026-09-23 00:47","pubTimestamp":1790095620,"startTime":"0","endTime":"0","summary":"Shares of biopharmaceutical company Maze Therapeutics jumped after competitor Vertex Pharmaceuticals reported positive study results for its kidney disease drug, signaling strong commercial potential ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TBXU","LU1069344957.HKD","LU2462157665.USD","IDNA","LU1035775433.USD","IE0009355771.USD","LU2324357040.USD","MAZE","LU0234570918.USD","IE00BJT1NW94.SGD","IE0002141913.USD","IE00B2B36J28.USD","LU1778281490.HKD","LU1674673428.USD","LU0889565916.HKD","BK4023","GNMX","IE00B894F039.SGD","LU0256863811.USD","LU1430594728.SGD","LU1815336091.USD","BK4532","PBE","LU2456880835.USD","BK4588","BK4567","LU1559883803.SGD","LU2362541513.USD","IBBQ","LU2237438978.USD","IE00BZ9MQY76.HKD","LU1093756168.USD","LU0058720904.USD","BIB","IE00B19Z9Z06.USD","XBI","LU0079474960.USD","VRTX","LU1585245621.USD","BBH","LU0432979614.USD","IE00BFTCPJ56.SGD","VERX","LU0289739699.SGD","LU2236285917.USD","IE00B19Z3581.USD","BK4585","IBB","LU2089984988.USD","SGXZ57979304.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669268991","title":"Update: US Equity Indexes, Crude Oil Prices Mixed in Midday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2669268991","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669268991?lang=en_us&edition=fundamental","pubTime":"2026-09-23 00:35","pubTimestamp":1790094905,"startTime":"0","endTime":"0","summary":"(Updates with index/price moves and company/geopolitical news from the first paragraph.)US equity indexes traded mixed, with materials leading gainers and financials fronting decliners after midday on","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IJR","JEPQ","GSLC","ACWI","TECS","SFY","TOPT","MNQmain","IBBQ","AMGN",".IXIC","SDOW","VYM","DDM","IJH","SCHD","SQQQ","REZ","QQQE","SPDN","SPXL","SPY",".SPX","HIBS",".DJI","QQQJ","MYMmain","NDX","VTV","GPIQ","QLD","QQQA","TSPY","DJX","RSPN","GRNY","RSP","SSO","EQR","SPXU","QQQ","RSPU","TBXU","SPYV","DIA","BIB","NOBL","QQQY","DGRW","IVE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669757123","title":"Analysts Offer Insights on Healthcare Companies: Eledon Pharmaceuticals (ELDN), Viking Therapeutics (VKTX) and Amgen (AMGN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669757123","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669757123?lang=en_us&edition=fundamental","pubTime":"2026-09-22 23:20","pubTimestamp":1790090418,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Eledon Pharmaceuticals (ELDN), Viking Therapeutics (...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-eledon-pharmaceuticals-eldn-viking-therapeutics-vktx-and-amgen-amgn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-eledon-pharmaceuticals-eldn-viking-therapeutics-vktx-and-amgen-amgn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BIB","LU0889565916.HKD","IE00B4R5TH58.HKD","OZEM","BK4139","LU0122379950.USD","ELDN","VKTX","IE0002141913.USD","PBE","LU2468319806.SGD","HCSG","IE00BFTCPJ56.SGD","LU0289739699.SGD","LABU","BK4599","LU0128526141.USD","IE00BJJMRZ35.SGD","BK4137","LU0868494617.USD","LU2112291526.USD","LU1061106388.HKD","IE00B2B36J28.USD","LU2242646821.SGD","LU0058720904.USD","LU1057294990.SGD","LU1571399168.USD","XBI","PJP","LU2242652126.USD","BK4588","IE0009355771.USD","XLV","LU1983299246.USD","THNR","LU0320765992.SGD","BK4533","SG9999001440.SGD","LU2089984988.USD","BBH","AMGN","IBBQ","LU0029874061.USD","LU0109394709.USD","BK4566","IBB","BK4585","TBXU","IE00BJT1NW94.SGD","BK4534"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669123184","title":"Amgen Inc Stock (AMGN) Moved Up by 3.90% on Sep 22: Facts Behind the Movement","url":"https://stock-news.laohu8.com/highlight/detail?id=2669123184","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669123184?lang=en_us&edition=fundamental","pubTime":"2026-09-22 23:15","pubTimestamp":1790090123,"startTime":"0","endTime":"0","summary":"• Amgen shares rose following positive Phase 3 OASIZ 301 trial results for dazodalibep.  \n• The company reported an annual revenue of $36.75B and a net profit of $7.71B.  \n• Analysts hold an average price target of $389.14 with a Hold rating.","market":"fut","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/market-movers/262180812-market-movers-amgn-20260922","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","LU0320765992.SGD","LU2468319806.SGD","LU1571399168.USD","BK4585","IE00BFTCPJ56.SGD","LU1023059063.AUD","BK4534","IBB","LU1057294990.SGD","BIB","IBBQ","04332","LU2242652126.USD","LU2112291526.USD","LU1983299246.USD","AMGN","BBH","IE00B4R5TH58.HKD","LU0889565916.HKD","IE0002141913.USD","BK4599","BK4581","LU0868494617.USD","LU0122379950.USD","IE00B2B36J28.USD","TBXU","LU0058720904.USD","IE00BJJMRZ35.SGD","LU2089984988.USD","LU0109394709.USD","IE0009355771.USD","BK4139","IE00BJT1NW94.SGD","LU2242646821.SGD","BK4533","LU1061106388.HKD","BK4588","SG9999001440.SGD","PJP","PBE","LU0289739699.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669821123","title":"Competitive profile of Amgen’s dazodalibep still ‘open question,’ says Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2669821123","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669821123?lang=en_us&edition=fundamental","pubTime":"2026-09-22 22:55","pubTimestamp":1790088920,"startTime":"0","endTime":"0","summary":"Citi says Amgen’s (AMGN) dazodalibep delivered “positive” Phase 3 results in systemic Sjogren’s, which reduces clinical risk for “a potentially und...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/competitive-profile-of-amgens-dazodalibep-still-open-question-says-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/competitive-profile-of-amgens-dazodalibep-still-open-question-says-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBH","IE0002141913.USD","LU1057294990.SGD","LU0889565916.HKD","TBXU","BK4588","SG9999001440.SGD","LU1983299246.USD","LU0868494617.USD","PJP","PBE","BK4139","IE00BFTCPJ56.SGD","LU2112291526.USD","IE00BJT1NW94.SGD","BK4566","LU0122379950.USD","BK4533","LU1061106388.HKD","IBB","LU1023059063.AUD","LU2089984988.USD","BIB","AMGN","LU0058720904.USD","BK4534","BK4581","LU0320765992.SGD","IBBQ","LU2242646821.SGD","LU2468319806.SGD","LU1571399168.USD","IE0009355771.USD","LU0289739699.SGD","BK4585","BK4599","IE00B2B36J28.USD","IE00B4R5TH58.HKD","LU0109394709.USD","IE00BJJMRZ35.SGD","LU2242652126.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669128999","title":"Truist sees ‘significant positive readthrough’ for Maze from Vertex data","url":"https://stock-news.laohu8.com/highlight/detail?id=2669128999","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669128999?lang=en_us&edition=fundamental","pubTime":"2026-09-22 22:30","pubTimestamp":1790087413,"startTime":"0","endTime":"0","summary":"Truist analyst Danielle Brill views Vertex’s (VRTX) positive Phase 2 topline data as a meaningful validation of APOL1 inhibition in classic APOL1-m...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/truist-sees-significant-positive-readthrough-for-maze-from-vertex-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/truist-sees-significant-positive-readthrough-for-maze-from-vertex-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0002141913.USD","LU0079474960.USD","LU1778281490.HKD","IE00B894F039.SGD","GNMX","IBB","BK4532","LU0889565916.HKD","LU0320765992.SGD","LU2089984988.USD","BK4023","SGXZ57979304.SGD","IE00B19Z3581.USD","BK4585","TBXU","IBBQ","LU1069344957.HKD","IE00B4R5TH58.HKD","LU2462157665.USD","LU1559883803.SGD","LU2362540622.SGD","LU1585245621.USD","IE00B19Z9Z06.USD","IDNA","LU0757428866.USD","PBE","VERX","LU1674673428.USD","LU0061475181.USD","IE00B19Z3B42.SGD","LU0823416689.USD","LU0256863811.USD","LU0289739699.SGD","IE00BZ9MQY76.HKD","BBH","LU2456880835.USD","LU1035775433.USD","LU1093756168.USD","LU1674673691.USD","LU2362541513.USD","BIB","IE0002270589.USD","LU0058720904.USD","LU1093756325.SGD","BK4533","VRTX","IE00B19Z9P08.USD","IE00BJJMRZ35.SGD","SG9999013999.USD","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669919128","title":"Maze jumps 25% to $27.99 after Vertex kidney disease data","url":"https://stock-news.laohu8.com/highlight/detail?id=2669919128","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669919128?lang=en_us&edition=fundamental","pubTime":"2026-09-22 22:25","pubTimestamp":1790087125,"startTime":"0","endTime":"0","summary":"10:23 EDT Maze jumps 25% to $27.99 after Vertex kidney disease data Published first on TheFly – the ultimate source for real-time, market-moving br...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maze-jumps-25-to-27-99-after-vertex-kidney-disease-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maze-jumps-25-to-27-99-after-vertex-kidney-disease-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VERX","IE00B19Z3581.USD","LU0432979614.USD","IE00BZ9MQY76.HKD","VRTX","LU0256863811.USD","LU1093756168.USD","LU0889565916.HKD","IE00B894F039.SGD","LU2362541273.HKD","BBH","BK4139","LU0320765992.SGD","LU1674673428.USD","PBE","LU1559883803.SGD","LU0058720904.USD","SG9999013999.USD","BK4567","LU0234570918.USD","IE0009355771.USD","IE00B19Z9P08.USD","LU2089984988.USD","BIB","IE00B19Z9Z06.USD","IE00BJT1NW94.SGD","SGXZ57979304.SGD","BK4023","IE0002141913.USD","LU0079474960.USD","BK4533","IBB","LU2362541513.USD","TBXU","IBBQ","IE0002270589.USD","LU1778281490.HKD","IDNA","LU2456880835.USD","GNMX","BK4585","LU2236285917.USD","LU0289739699.SGD","IE00BFTCPJ56.SGD","LU0109394709.USD","LU1585245621.USD","LU1815336091.USD","LU2417539215.USD","LU1093756325.SGD","LU2462157665.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669470171","title":"Amgen Rises After Autoimmune Drug Meets Late-Stage Trial Goal","url":"https://stock-news.laohu8.com/highlight/detail?id=2669470171","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669470171?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:48","pubTimestamp":1790084894,"startTime":"0","endTime":"0","summary":"BUZZ-Amgen rises after autoimmune drug meets late-stage trial goal** Shares of drugmaker AmgenAMGN.Orise 2.4% to $402.69** Co says its experimental drug, dazodalibep, for Sjogren's diseasemet the main goalof reducing disease activity in a late-stage trial** Sjogren's disease is an autoimmune disorder that causes dryness of the eyes, mouth and other parts of the body, along with fatigue and chronic pain** Drug showed a statistically significant and clinically meaningful improvement at week 48; most side effects were mild to moderate** Co plans to present detailed results at an upcoming medical meeting** Including session's move, AMGN up 23.1% YTD","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nL4N45E0WO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","PJP","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","BK4581","IBBQ","BK4534","IE0002141913.USD","PBE","LU0109394709.USD","BIB","BBH","LU2089984988.USD","IBB","LU1061106388.HKD","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","BK4588","LU0320765992.SGD","LU1571399168.USD","LU2468319806.SGD","IE0009355771.USD","SG9999001440.SGD","LU2242646821.SGD","BK4599","LU0122379950.USD","LU0868494617.USD","LU0289739699.SGD","LU1057294990.SGD","IE00B4R5TH58.HKD","BK4533","BK4585","LU2112291526.USD","LU2242652126.USD","LU1983299246.USD","AMGN","LU1023059063.AUD","TBXU","LU0889565916.HKD","BK4139","LU0058720904.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669147050","title":"Amgen Says Dazodalibep Meets Primary Endpoint in Phase 3 Sjögren's Disease Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2669147050","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669147050?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:45","pubTimestamp":1790084715,"startTime":"0","endTime":"0","summary":"Sept 22 (Reuters) - Amgen Inc::*AMGEN: PHASE 3 OASIZ 303 STUDY OF DAZODALIBEP IN MODERATE-TO-SEVERE SYMPTOMATIC SJGREN’S DISEASE EXPECTED TO COMPLETE IN Q4 2026*AMGEN: DAZODALIBEP MEETS PRIMARY ENDPOI","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nRSDcc0x9T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PBE","LU1061106388.HKD","LU0122379950.USD","IE00BJJMRZ35.SGD","BIB","LU0320765992.SGD","LU2242646821.SGD","LU2242652126.USD","LU0868494617.USD","LU2468319806.SGD","LU1023059063.AUD","AMGN","BBH","LU0109394709.USD","LU2089984988.USD","LU0289739699.SGD","LU1057294990.SGD","BK4566","LU1571399168.USD","PJP","IE00B4R5TH58.HKD","IE0009355771.USD","IE00BFTCPJ56.SGD","SG9999001440.SGD","IE00B2B36J28.USD","BK4585","LU1983299246.USD","BK4599","IBB","BK4533","IE0002141913.USD","BK4139","LU0889565916.HKD","TBXU","LU2112291526.USD","BK4534","BK4588","BK4581","LU0058720904.USD","IE00BJT1NW94.SGD","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669147177","title":"Amgen Shares up 3% After Co's Autoimmune Disease Drug Succeeds in Late-Stage Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2669147177","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669147177?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:36","pubTimestamp":1790084178,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nL4N45E0VV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4566","IE00B2B36J28.USD","IE00B4R5TH58.HKD","BK4534","LU0889565916.HKD","LU2468319806.SGD","LU2112291526.USD","BBH","LU1571399168.USD","LU0320765992.SGD","IE00BFTCPJ56.SGD","AMGN","PBE","BK4585","LU1983299246.USD","SG9999001440.SGD","IBB","LU0289739699.SGD","IE00BJJMRZ35.SGD","IE0002141913.USD","IBBQ","TBXU","LU0868494617.USD","LU1057294990.SGD","LU2089984988.USD","LU0058720904.USD","LU0109394709.USD","LU0122379950.USD","BK4533","PJP","LU1061106388.HKD","LU2242646821.SGD","IE00BJT1NW94.SGD","BIB","BK4581","BK4599","BK4588","BK4139","LU1023059063.AUD","IE0009355771.USD","LU2242652126.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669414223","title":"Amgen Says Phase 3 Trial Shows Dazodalibep Cuts Systemic Disease Activity in Sjögren’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2669414223","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669414223?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:04","pubTimestamp":1790082271,"startTime":"0","endTime":"0","summary":"Amgen says Phase 3 trial shows dazodalibep cuts systemic disease activity in Sjgren’s diseaseAmgen reported positive topline Phase 3 results for dazodalibep in adults with moderate-to-severe systemic ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nNDL63L4Jz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1571399168.USD","TBXU","IE00B4R5TH58.HKD","LU1061106388.HKD","IE0009355771.USD","LU2468319806.SGD","LU1057294990.SGD","IE00BJT1NW94.SGD","IE0002141913.USD","IE00B2B36J28.USD","LU0122379950.USD","LU0889565916.HKD","LU2242652126.USD","BK4534","LU1023059063.AUD","LU0868494617.USD","PBE","BK4588","AMGN","BK4581","IBBQ","LU2112291526.USD","SG9999001440.SGD","LU0320765992.SGD","LU0058720904.USD","PJP","BIB","LU1983299246.USD","IE00BJJMRZ35.SGD","BK4566","BK4139","LU0109394709.USD","BK4533","BBH","IE00BFTCPJ56.SGD","BK4599","LU0289739699.SGD","BK4585","IBB","LU2242646821.SGD","LU2089984988.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669142464","title":"Vertex Pharmaceuticals Incorporated Says Inaxaplin Reduces UACR by -42.7% at Week 13 in AMKD with Modest Proteinuria","url":"https://stock-news.laohu8.com/highlight/detail?id=2669142464","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669142464?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:02","pubTimestamp":1790082154,"startTime":"0","endTime":"0","summary":"Sept 22 (Reuters) - Vertex Pharmaceuticals Incorporated::*VERTEX ANNOUNCES POSITIVE RESULTS FROM PHASE 2B AMPLIFIED STUDY OF INAXAPLIN IN ADDITIONAL POPULATIONS OF PEOPLE WITH APOL1-MEDIATED KIDNEY DI","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nRSD66vtCD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0417517546.SGD","LU2362540622.SGD","TBXU","PBE","LU2468319806.SGD","IE0002141913.USD","IE00B894F039.SGD","IE00B19Z3B42.SGD","IBB","IE00B19Z9Z06.USD","VRTX","LU0234570918.USD","LU0289739699.SGD","LU0320765992.SGD","LU2236285917.USD","BK4585","LU1674673691.USD","BK4588","BBH","IE00B2B36J28.USD","IE0009355771.USD","LU1035775433.USD","LU2362541273.HKD","LU0061475181.USD","LU1093756168.USD","LU0889565916.HKD","BK4139","LU2089984988.USD","IE00BFTCPJ56.SGD","LU0256863811.USD","IE00B19Z9P08.USD","LU0432979614.USD","LU0079474960.USD","LU2362541513.USD","IBBQ","LU2417539215.USD","IE00B4R5TH58.HKD","LU2237438978.USD","BK4567","SG9999013999.USD","BK4532","IE00BJT1NW94.SGD","LU1093756325.SGD","SG9999001176.SGD","BIB","BK4533","IDNA","GNMX","LU0823416689.USD","IE00BZ9MQY76.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669142967","title":"Amgen Announces Positive Topline Phase 3 Results for Dazodalibep in Moderate-to-Severe Systemic SjÖGren's Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2669142967","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669142967?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:00","pubTimestamp":1790082029,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nFWN45E0FE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SG9999001440.SGD","BK4533","IE00B4R5TH58.HKD","IBB","LU1061106388.HKD","LU0109394709.USD","LU0868494617.USD","BK4566","LU1571399168.USD","BK4599","LU0320765992.SGD","BK4581","TBXU","LU0889565916.HKD","IE00BJJMRZ35.SGD","LU2112291526.USD","IE0002141913.USD","PBE","BK4534","IE00BJT1NW94.SGD","LU2468319806.SGD","BK4585","IE0009355771.USD","LU1983299246.USD","BK4139","LU1057294990.SGD","AMGN","PJP","LU0122379950.USD","BIB","IE00BFTCPJ56.SGD","LU0058720904.USD","LU1023059063.AUD","BBH","BK4588","IE00B2B36J28.USD","LU2242646821.SGD","LU0289739699.SGD","LU2089984988.USD","IBBQ","LU2242652126.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669142945","title":"Amgen: Dazodalibep Showed Statistically Significant & Clinically Meaningful Improvement in Systemic Disease Activity","url":"https://stock-news.laohu8.com/highlight/detail?id=2669142945","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669142945?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:00","pubTimestamp":1790082000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nP8N3Z20GZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0889565916.HKD","PJP","BBH","BIB","BK4534","LU2468319806.SGD","BK4581","LU1571399168.USD","LU2089984988.USD","IE00BJJMRZ35.SGD","BK4599","BK4588","LU0320765992.SGD","BK4585","IE0002141913.USD","LU0109394709.USD","LU2242646821.SGD","LU0868494617.USD","IE0009355771.USD","LU1023059063.AUD","AMGN","IE00B4R5TH58.HKD","IE00B2B36J28.USD","LU1057294990.SGD","LU0058720904.USD","LU0122379950.USD","LU1061106388.HKD","LU1983299246.USD","BK4533","LU0289739699.SGD","IBBQ","PBE","BK4139","BK4566","LU2242652126.USD","LU2112291526.USD","SG9999001440.SGD","TBXU","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669142617","title":"Amgen: Phase 3 Oasiz 303 Study of Dazodalibep in Moderate-to-Severe Symptomatic SjÖGren’s Disease Expected to Complete in Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2669142617","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669142617?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:00","pubTimestamp":1790082000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nP8N3Z20GZ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1057294990.SGD","BK4534","IE00BJJMRZ35.SGD","BBH","PBE","LU0320765992.SGD","BK4599","LU0122379950.USD","LU0889565916.HKD","LU0868494617.USD","BK4585","BIB","LU1983299246.USD","BK4581","SG9999001440.SGD","IE0009355771.USD","IE0002141913.USD","LU0058720904.USD","IBB","AMGN","IE00B2B36J28.USD","IBBQ","LU2112291526.USD","LU1023059063.AUD","IE00B4R5TH58.HKD","BK4588","IE00BFTCPJ56.SGD","BK4566","LU0289739699.SGD","IE00BJT1NW94.SGD","PJP","LU2242646821.SGD","LU2242652126.USD","LU1061106388.HKD","LU2089984988.USD","LU2468319806.SGD","BK4533","TBXU","LU0109394709.USD","LU1571399168.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669425861","title":"Vertex Pharmaceuticals Reports Positive Results for Inaxaplin Kidney Disease Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2669425861","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669425861?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:50","pubTimestamp":1790081406,"startTime":"0","endTime":"0","summary":"Vertex Pharmaceuticals  said Tuesday that a phase 2b study of inaxaplin to treat patients with APOL1-mediated kidney disease showed a 42.7% protein reduction, and a 17.3% reduction in patients who also have type 2 diabetes.The company said the drug showed a favorable safety profile with no drug-related serious adverse events reported. It said headaches were the most frequent side effect, which affected 7.3% of trial participants.The company said the reduction was measured after 13 weeks of treatment. Vertex said it has finished enrolling patients in a larger Phase 2/3 trial of inaxaplin.Shares of Vertex were up 2.2% pre-bell.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IBB","IE00BZ9MQY76.HKD","IE0009355771.USD","SG9999001176.USD","LU1674673428.USD","IE00B19Z9P08.USD","LU0757428866.USD","IE00B19Z3581.USD","LU2236285917.USD","LU2468319806.SGD","BK4532","LU2089984988.USD","BBH","BK4139","BK4567","LU1559883803.SGD","LU1778281490.HKD","BK4023","TBXU","LU0061475181.USD","IE0002141913.USD","SGXZ57979304.SGD","SG9999013999.USD","IDNA","LU2417539215.USD","IE00BJJMRZ35.SGD","GNMX","PBE","IE0002270589.USD","LU1069344957.HKD","IE00BJT1NW94.SGD","LU1093756325.SGD","BK4533","LU2324357040.USD","LU0566484027.USD","LU2362540622.SGD","LU1035775433.USD","IE00B894F039.SGD","LU0058720904.USD","IBBQ","SG9999001176.SGD","VRTX","IE00B19Z9Z06.USD","LU1674673691.USD","BIB","LU0079474960.USD","BK4588","VERX","LU2362541513.USD","LU1815336091.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669144313","title":"Vertex Pharmaceuticals announces positive results from Phase 2b inaxaplin study","url":"https://stock-news.laohu8.com/highlight/detail?id=2669144313","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669144313?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:15","pubTimestamp":1790079331,"startTime":"0","endTime":"0","summary":"The company states: “Vertex Pharmaceuticals (VRTX) announced positive results from the Phase 2b AMPLIFIED study of inaxaplin in people with APOL1-m...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vertex-pharmaceuticals-announces-positive-results-from-phase-2b-inaxaplin-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vertex-pharmaceuticals-announces-positive-results-from-phase-2b-inaxaplin-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BFTCPJ56.SGD","LU1430594728.SGD","IE00B19Z3B42.SGD","LU0061475181.USD","LU1585245621.USD","IE00B19Z9Z06.USD","IBBQ","IE0009355771.USD","LU2089984988.USD","LU2237438978.USD","BIB","IE00BJT1NW94.SGD","SG9999013999.USD","LU0432979614.USD","VERX","LU1093756325.SGD","LU0234570918.USD","LU2462157665.USD","IE00B19Z9P08.USD","LU1674673428.USD","LU1815336091.USD","IE0002141913.USD","BK4532","GNMX","LU1778281490.HKD","IE00B4R5TH58.HKD","LU0289739699.SGD","BBH","IE00B2B36J28.USD","LU1035775433.USD","TBXU","IBB","IE00B19Z3581.USD","LU0109394709.USD","SG9999001176.SGD","BK4139","LU0757428866.USD","LU0823416689.USD","LU2236285917.USD","BK4567","BK4023","LU1674673691.USD","BK4588","IDNA","LU1093756168.USD","LU2362540622.SGD","PBE","VRTX","LU0320765992.SGD","LU0256863811.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":7,"totalSize":200,"code":"91000000","status":"200"}]}}